ProCE Banner Activity

KEYNOTE-355: Pembrolizumab + Chemotherapy for Previously Untreated Advanced Triple-Negative Breast Cancer

Slideset Download
Conference Coverage
Adding pembrolizumab to chemotherapy improves PFS in mTBC with PD-L1 CPS 10 or higher

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono